In recent years, positron emission tomography (PET) with radiopharmaceuticals that target prostate-specific membrane antigen (PSMA) has become the mainstay for imaging patients with prostate cancer owing to its improved sensitivity and diagnostic performance compared with conventional imaging methods such as computed tomography (CT), magnetic resonance imaging (MRI), and bone scintigraphy [2,4]. The gene discussed is FOLH1; the disease is prostate cancer.